Haemonetics Co. (NYSE:HAE) saw a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 1,270,000 shares, a growth of 25.7% from the January 15th total of 1,010,000 shares. Based on an average daily trading volume, of 346,200 shares, the short-interest ratio is presently 3.7 days. Approximately 2.5% of the company’s stock are sold short.

Several equities analysts have commented on the stock. Barrington Research reissued a “buy” rating and issued a $141.00 price target on shares of Haemonetics in a research report on Monday, November 4th. Needham & Company LLC reissued a “buy” rating and issued a $142.00 price target on shares of Haemonetics in a research report on Tuesday, February 4th. Raymond James raised their price target on shares of Haemonetics from $145.00 to $150.00 and gave the company an “outperform” rating in a research report on Wednesday, February 5th. Finally, ValuEngine cut shares of Haemonetics from a “hold” rating to a “sell” rating in a research report on Thursday, February 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $144.33.

Shares of HAE stock opened at $119.71 on Friday. The company has a quick ratio of 1.28, a current ratio of 2.27 and a debt-to-equity ratio of 0.54. Haemonetics has a 52 week low of $80.24 and a 52 week high of $140.36. The stock has a market capitalization of $6.03 billion, a PE ratio of 78.24, a P/E/G ratio of 2.64 and a beta of 0.79. The firm has a 50 day moving average of $114.31 and a two-hundred day moving average of $122.27.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Tuesday, February 4th. The medical instruments supplier reported $0.94 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.76 by $0.18. Haemonetics had a net margin of 7.98% and a return on equity of 27.78%. The business had revenue of $259.00 million for the quarter, compared to analyst estimates of $255.40 million. During the same period last year, the business earned $0.63 EPS. The company’s revenue was up 4.7% on a year-over-year basis. Analysts expect that Haemonetics will post 3.37 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Smithfield Trust Co. raised its holdings in shares of Haemonetics by 18.8% in the 3rd quarter. Smithfield Trust Co. now owns 570 shares of the medical instruments supplier’s stock valued at $72,000 after purchasing an additional 90 shares in the last quarter. Louisiana State Employees Retirement System raised its stake in Haemonetics by 0.8% during the 4th quarter. Louisiana State Employees Retirement System now owns 12,300 shares of the medical instruments supplier’s stock worth $1,413,000 after acquiring an additional 100 shares in the last quarter. Utah Retirement Systems raised its stake in Haemonetics by 1.3% during the 4th quarter. Utah Retirement Systems now owns 7,585 shares of the medical instruments supplier’s stock worth $872,000 after acquiring an additional 100 shares in the last quarter. M&T Bank Corp raised its stake in Haemonetics by 2.5% during the 4th quarter. M&T Bank Corp now owns 4,232 shares of the medical instruments supplier’s stock worth $487,000 after acquiring an additional 103 shares in the last quarter. Finally, Municipal Employees Retirement System of Michigan raised its stake in Haemonetics by 1.2% during the 4th quarter. Municipal Employees Retirement System of Michigan now owns 9,420 shares of the medical instruments supplier’s stock worth $1,082,000 after acquiring an additional 110 shares in the last quarter. Institutional investors and hedge funds own 96.74% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

See Also: How to identify percentage decliners

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.